Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Blueprint Medicines Corporation

Biotech SG&A Trends: A Decade of Strategic Growth

__timestampBio-Techne CorporationBlueprint Medicines Corporation
Wednesday, January 1, 2014607160007890000
Thursday, January 1, 201511940100014456000
Friday, January 1, 201614087900019218000
Sunday, January 1, 201719924300027986000
Monday, January 1, 201824063600047928000
Tuesday, January 1, 201926435900096388000
Wednesday, January 1, 2020260583000157743000
Friday, January 1, 2021324951000195293000
Saturday, January 1, 2022372766000237374000
Sunday, January 1, 2023378378000295141000
Monday, January 1, 2024396826000359272000
Loading chart...

Infusing magic into the data realm

Navigating SG&A Expenses in the Biotech Sector

In the dynamic world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustainable growth. Bio-Techne Corporation and Blueprint Medicines Corporation, two prominent players, have shown distinct trends in their SG&A expenses over the past decade. From 2014 to 2023, Bio-Techne's SG&A expenses surged by over 500%, reflecting strategic investments in growth and innovation. Meanwhile, Blueprint Medicines saw an exponential increase of nearly 3,700% in the same period, highlighting its aggressive expansion strategy. Notably, Bio-Techne's expenses peaked in 2024, while Blueprint's data for that year remains unavailable, indicating potential reporting delays or strategic shifts. These trends underscore the importance of cost management in maintaining competitive advantage and driving innovation in the biotech industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025